United Therapeutics Corporation (UTHR)
United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates
United Therapeutics (UTHR) came out with quarterly earnings of $5.82 per share, missing the Zacks Consensus Estimate of $6.73 per share. This compares to earnings of $6.63 per share a year ago.
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
United Therapeutics (UTHR) to Report Q1 Results: Wall Street Expects Earnings Growth
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics: The Future Lies With Manufactured Organs
United Therapeutics is rated a long-term Buy, driven by its pioneering efforts in xenotransplantation and organ manufacturing. Current revenue relies heavily on treprostinil-based therapies, but future growth is expected from FDA-approved lab-grown organs by 2030. Patent expirations and competition present near-term risks, yet margins have improved and the company remains well-positioned for transition.
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
United Therapeutics: Maintaining 'Strong Buy' On Second TETON Study Program Win
United Therapeutics Corporation maintains a Strong Buy rating after a second phase 3 win for nebulized Tyvaso in idiopathic pulmonary fibrosis [IPF]. UTHR achieved superior FVC improvement in TETON-1 [130.1 mL] versus TETON-2 [95.6 mL], both statistically significant, supporting sNDA submission for IPF by summer of this year. Priority Review will be sought for Tyvaso in IPF, with further expansion targeted via ongoing TETON-PPF for progressive pulmonary fibrosis.
UTHR Stock Rises 12.5% on Promising Data From TETON-1 Tyvaso Study
United Therapeutics jumps 12.5% as phase III TETON-1 data show strong lung function gains for Tyvaso in IPF, paving the way for a potential FDA filing.
United Therapeutics (UTHR) Moves 12.5% Higher: Will This Strength Last?
United Therapeutics (UTHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
United Therapeutics shares surge after positive IPF trial results
Shares of United Therapeutics Corporation (NASDAQ:UTHR) jumped more than 13% on Monday morning following the announcement of positive topline results from the Phase 3 TETON‑1 trial of its inhaled therapy, Tyvaso, in idiopathic pulmonary fibrosis (IPF). Jefferies analysts called the results “highly clinically meaningful,” noting that the trial met its primary endpoint with a change in absolute forced vital capacity (FVC) of 130.1 milliliters at week 52 compared with placebo (p
United Therapeutics (UTHR) Up 5.7% Since Last Earnings Report: Can It Continue?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
United Therapeutics Stock Surges 32% in 6 Months: Here's Why
UTHR shares jump 32% in six months as Tyvaso sales surge, earnings grow and Phase III TETON-2 data open a potential new market in IPF.
United Therapeutics: Ralinepag Is The Ultimate Defense Against Yutrepia (Rating Upgrade)
United Therapeutics is upgraded to 'Buy', as ralinepag's Phase 3 success de-risks the pipeline and positions UTHR for further upside. Ralinepag's blockbuster potential, TYVASO's IPF expansion, and a strategic shift away from royalty-heavy products underpin UTHR's attractive valuation. My base case fair value is ~$590/share, with scenario analysis indicating a solid margin of safety and upside toward $800 in bullish conditions.
